Immunome, Inc. (IMNM)

NCM – Real vaqt narxi. Valyuta: USD

27.99

+1.74 (6.63%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

27.70

-0.29 (-1.04%)

Bozordan keyin: Aug 12, 2026, 4:26 PM EDT

11.08.2026

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. “We continue to execute against our strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients,” said Clay B. Siegall, Ph.D., President and Chief Executive Of.

06.08.2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the Company's 2024 Induc.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

06.08.2026

Immunome, Inc. (IMNM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunome, Inc. (IMNM)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Immunome, Inc. (IMNM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunome, Inc. (IMNM)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)